Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN N versus PENICILLIN G SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN N versus PENICILLIN G SODIUM.
OMNIPEN-N vs PENICILLIN G SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
2-4 million units intravenously every 4 hours for moderate to severe infections; up to 24 million units/day for severe infections (e.g., meningitis, endocarditis).
None Documented
None Documented
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
30-60 minutes in normal renal function; prolonged to 7-10 hours in anuria.
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Primarily renal (60-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic